Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Pembrolizumab plus chemoradiotherapy significantly improves survival in high-risk cervical cancer patients.
Meta-analysis reveals rucaparib's efficacy in treating recurrent ovarian cancer, especially in BRCA carriers.
Phase 2 trial evaluates PARP inhibitor and antiangiogenic agent in recurrent endometrial cancer.
Study compares sequential vs. combination immunotherapy in platinum-resistant ovarian cancer patients.
Phase III trial of ofranergene obadenovec plus paclitaxel fails to improve outcomes in ovarian cancer
Durvalumab plus chemo followed by durvalumab +/- olaparib improves PFS in advanced endometrial cancer
Study shows olaparib rechallenge improves progression-free survival in platinum-sensitive relapsed ovarian cancer